JAMA ophthalmology۲۰۲۵۱۸ استنادنمایه شده در PubMed
Helen Tesfaye, Julie M Paik, Miin Roh, Phyo T Htoo, Heidi Zakoul, Niklas Schmedt, Lisette Koeneman, Deborah J Wexler, Elisabetta Patorno
چکیده
Empagliflozin might lower the risk of diabetic retinopathy (DR) by preventing retinal pericyte loss. However, the role of empagliflozin with respect to DR in patients with type 2 diabetes (T2D) remains unclear. To compare the risk of incident nonproliferative DR (NPDR) and DR progression in…
متن کامل چکیده در سایت ناشر در دسترس است.
DOI: 10.1001/jamaophthalmol.2024.5219